Stock Price Quote

WOCKHARDT LTD.

NSE : WOCKPHARMABSE : 532300ISIN CODE : INE049B01025Industry : Pharmaceuticals & DrugsHouse : Wockhardt
BSE551.6016.35 (+3.05 %)
PREV CLOSE ( ) 535.25
OPEN PRICE ( ) 540.00
BID PRICE (QTY) 551.60 (1575)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 36328
TODAY'S LOW / HIGH ( )530.65 554.00
52 WK LOW / HIGH ( )145.35 630
NSE551.4017.85 (+3.35 %)
PREV CLOSE( ) 533.55
OPEN PRICE ( ) 543.90
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 551.40 (147)
VOLUME 328482
TODAY'S LOW / HIGH( ) 540.00 555.00
52 WK LOW / HIGH ( )145.15 630
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 08-07 1999
Management Info
Habil Khorakiwala - Chairman Murtaza Khorakiwala - Managing Director
Registered Office

Address D-4, M. I. D. C,Chikalthana, ,
Chhatrapati Sambhajinagar - (Aurangabad),
Maharashtra-431006

Phone 0240-6632222 / 6694444

Email investorrelations@wockhardt.com

Website www.wockhardt.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, Luxembourg, MCX

NEWS

19Mar Wockhardt informs about closure of tra
Pursuant to Company’s ‘Code of Conduct for Regulating, Monitoring and Re..
26Feb Wockhardt informs about investor prese
Pursuant to Regulation 30 of the Securities and Exchange Board of India..
19Jan Announcement under Regulation 30 (LOD
We wish to inform you that the Share Allotment Committee of the Board ha..
12Dec Wockhardt completes pivotal Phase 3 pn
Wockhardt has completed the pivotal Phase 3 pneumonia Study of its macro..
12Dec Wockhardt shines on completing pivotal
Wockhardt is currently trading at Rs. 403.05, up by 19.20 points or 5.00..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit-740-4660
Gross Profit -740 -5130
Operating Profit 3001370
Net Sales 288010720

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Hester Biosciences (BSE)
peergroup  1435.00 (8.31%)
M.Cap ( in Cr)1145.87
IOL Chem & Pharma (BSE)
peergroup  403.00 (11.48%)
M.Cap ( in Cr)2401.06
SMS Lifesciences (BSE)
peergroup  640.95 (4.67%)
M.Cap ( in Cr)190.47
Samrat Pharmachem (BSE)
peergroup  347.55 (7.45%)
M.Cap ( in Cr)109.87
Pfizer (BSE)
peergroup  4350.00 (0.44%)
M.Cap ( in Cr)19955.85

Shareholding Pattern

PROMOTERS 54.93%
NON-INSTITUTION 40.59%
MUTUAL FUNDS/UTI 0.09%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Wockhardt Ltd.

Wockhardt Ltd. was incorporated in the year 1999. Its today's share price is 551.6. Its current market capitalisation stands at Rs 7955.19 Cr. In the latest quarter, company has reported Gross Sales of Rs. 10740 Cr and Total Income of Rs.11390 Cr. The company's management includes Amelia Fernandes, Rashmi Mamtura, Davinder Singh Brar, Zahabiya Khorakiwala, Murtaza Khorakiwala, Huzaifa Khorakiwala, Akhilesh Gupta, Vinesh Kumar Jairath, Tasneem Mehta, Sanjaya Baru, Aman Mehta, Habil Khorakiwala.

It is listed on the BSE with a BSE Code of 532300 , NSE with an NSE Symbol of WOCKPHARMA and ISIN of INE049B01025. It's Registered office is at D-4, M. I. D. C,Chikalthana, Chhatrapati Sambhajinagar - (Aurangabad)-431006, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Arthur Andersen & Associates, BSR & Co LLP, Haribhakti & Co, Haribhakti & Co LLP, SR Batliboi & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.